Paradigm Genetics - eine 1000 Prozentchance?! - 500 Beiträge pro Seite

[ChrishBaur]

Dieses Thread richtet sich an die Biotech-Freaks. Ich beobachte seit längerem die Aktie Paradigm Genetics und war auch kurzzeitig investiert (Verkauf mit 30% plus). Nun bin ich dabei, ein langfristiges Biotechdepot errichten und spiele mit dem Gedanken, Paradigm aufzunehmen. Wie denkt ihr über den Wert? Und welche weiteren Favoriten habt ihr noch? Meine weiteren Titel lauten:

1. Stemcells
2. Ligand Pharma
3. Aurora Bioscience
4. Vertex
5. Trega Bioscience

Ich sehe euren Antworten erwartungsvoll entgegen!

(Dies soll kein Thread für Pushversuche aussichtsloser Aktien sein!!!)

[KostosRevenge]

Mich würde interessieren, warum du diese Werte bevorzugst.

Meine Favoriten sind: Amgen und Genentech wegen der enormen Produktpipeline in der klinischen Forschung, beide Werte stehen vor der Zulassung mehrerer neuer Medikamente in den nächsten 2-3 Jahren. Dadurch sind enorme Umsatz- und Gewinnzuwächse zu erwarten.

Und als spekulativen Hoffnungswert setze ich auf Trimeris, die möglicherweise vor einem Durchbruch in der AIDS-Behandlung stehen. Die Homepage von Trimeris bietet interessante Einblicke über den aktuellen Stand der klinischen Forschung.

Gruß
KostosRevenge

[frank3]

Hallo Leute,
habe mir auch ein paar Stücke Paradigm Genetics (300) ins Depot gelegt; bin damit aber zur Zeit im Minus.
Habe bisher mit Biotecs unterschiedliche Erfahrungen gemacht; so sind mir Progenics, Xoma und Genelabs
um mehr als 70% abgeschmiert, ich konnte gar nicht so schnell gucken, da waren die Kurse im Eimer.
Auf der anderen Seite habe ich bei Unternehmen, die nicht in der Medikamentenforschung tätig sind, größten-
teils gute Erfolge erzielen können. Chrish, stimme Dir deshalb bei Aurora Biosciences uneingeschränkt zu.
Unter Risikoaspekten würde ich Genentec und Milllennium bei den Forschungsunternehmen bevorzugen.
Mein Biotechdepotanteil sieht derzeit wie folgt aus:

1. Qiagen 800 St. (+732%)
2. Abgenix 400 St.( +508%)
3. Cybio 100 St. (+146%)
4. Paradigm Genetics 300 St. (-20,7%)
5. Lexicon Genetics 100 St. (+ 9,5%)
6. Genomic solutions 200 St. (-26,5%)
7. Hyseq 100 St. (+42,4%)
8. Avigen 100 St. (+19,1%)
9. Progenics 100 St. (-69,5%)

Da ich tagsüber arbeite und einige Aktien sehr markteng sind, trade ich wenig. Xoma und Genlabs habe ich
mit rd. -70% verkauft, Pech gehabt. Avigen und Progenics würde ich nicht mehr kaufen wollen, zu Paradigm
Genetics würde ich Lexicon Genetics ins Depot nehmen, um später die schlechter laufende Aktie in die bessere
zu switchen. Also good luck chrish und Kostos; da keiner vollkommen ist, bin ich für konstruktive Kritik an
meinem Biotechanteil dankbar.

Gruß Frank

[woolfe]

Könnte auch aufgrund der BSE-Diskussion profitieren:
3.Nov.99
www.prionics.com
Prionics AG and Paradigm Genetics Start Collaboration on Tests for Rapid Detection of "Mad Cow Disease" in Cattle and Creutzfeldt-Jakob (CJD) in Humans.

Prionics AG and Paradigm Genetics, Inc. of the United States have started a joint development of innovative diagnostics for the rapid detection of Bovine Spongiform E ncephalopathy (BSE) in cattle and Creutzfeldt-Jakob Disease (CJD) in humans. Prionics AG has established itself as a leader in prion diagnostics with the introduction of the concept of Active Targeted BSE-Surveillance based on the rapid diagnostic test Prionics-Check. New diagnostic developments will focus on both post mortem and ante mortem tests for animals and humans. Paradigm Genetics brings to the collaboration its expertise in the design and development of novel assay formats, specifically its vast knowledge and experience in the development of rapid and high throughput testing techniques that can be performed outside the research laboratory.

[trendwatcher]

Paradigm (936980) hat von der aktuellen BSE-Diskussion bisher offenbar nicht profitiert.

Das könnte sich rasch und kräftig ändern, wenn der IR-Abteilung von Paradigm dazu in den nächsten Tagen was einfällt ...

trendwatcher

[[KERN]Codex]

Hey

@KostosRevenge

Kannst du mir mehr Informationen über Trimeris posten?
Ich denke, dass der Bereich AIDS in der Zukunft sehr interessant sein wird!

Gruß Codex

[trendwatcher]

Es gibt nach wie vor Einkaufkurse - und gute Nachrichten:
Paradigm kooperiert nun auch mit der Bayer AG ... (s.u.)

trendwatcher

_________________________________________________________

RESEARCH TRIANGLE PARK, N.C., Dec. 5 /PRNewswire/ --

Paradigm Genetics, Inc. (Nasdaq: PDGM), a functional genomics company, today announced it has delivered new assays for high-throughput screening to Bayer AG (NYSE: BAYZY). The delivery of these assays triggers undisclosed milestone payments to Paradigm from Bayer.

The new assays are designed to identify novel classes of safe and effective herbicides. Bayer scientists will use the assays to screen their extensive compound collection for promising product leads. Paradigm will receive additional milestone payments during the course of the agreement and royalty payments on products discovered.

"We are able to meet and surpass milestones because of our expertise in functional genomics and the speed of our GeneFunctionFactory(TM) continues to improve," John Ryals, Ph.D., CEO and President of Paradigm Genetics, Inc. "We look forward to future deliveries of herbicide assays to Bayer for use in its high-throughput screening facility."

Paradigm`s research collaboration with Bayer began in October 1998. Since that time, Paradigm has achieved several milestones, including delivery of two versions of its customized FunctionFinder(TM) bioinformatics system and a high-throughput screening assay.

Paradigm brings to the collaboration its expertise in gene function analysis and bioinformatics. Paradigm`s high-throughput analysis methodology is comprised of a series of proprietary analytical processes combined with a computerized knowledge base of plant and fungal gene function information. Bayer brings extensive knowledge of how to develop safe and effective crop protection products, including herbicides, fungicides and insecticides. (...)

[woolfe]

Endlich auch eine Nachricht von PDGM:
Thursday December 14, 6:30 pm Eastern Time
Press Release
SOURCE: Paradigm Genetics, Inc.
Paradigm Genetics and Prionics Extend Collaborative Agreement to Develop New Tests for Rapid Detection of Creutzfeldt-Jakob Disease (CJD) in Humans and `Mad Cow Disease` in Cattle
RESEARCH TRIANGLE PARK, N.C., and ZURICH, Switzerland, Dec. 14

/PRNewswire/ -- Paradigm Genetics, Inc. (Nasdaq: PDGM - news), a functional genomics
company, and Prionics AG of Switzerland, have extended a collaborative
agreement to co-develop and co-market innovative blood-based diagnostics for
the rapid detection of Creutzfeld-Jakob Disease (CJD) in humans and Bovine
Spongiform Encephalopathy (BSE, commonly known as Mad Cow Disease) in cattle.
These blood-based diagnostics could be used to pre-symptomatically detect the
diseases in both humans and cattle. Both parties will continue to share
development costs and Paradigm will receive a royalty on any product(s)
developed as a result of the collaboration.
Paradigm brings to the collaboration its technological expertise and resources required to design and develop novel assays through to product development. Specifically, Paradigm contributes its vast knowledge and experience in the development of rapid, high-throughput testing techniques that can be performed within and outside the research laboratory. In addition, Paradigm will assist with validation and clinical trials of the diagnostics resulting from the collaboration. Prionics provides proprietary immunological reagents and expertise in the field of prion diseases, jointly described as TSEs (transmissable spongiform encephalitis).

``The recent detection of BSE in France and Germany through the use of Prionics®-Check confirms the need for faster, better tests to detect disease during the pre-symptomatic stages. The ability to test for the presence of prions in blood would be a major step forward in developing a rapid, reliable and simple detection assay. We believe it is possible to develop an effective diagnostic that uses whole blood samples rather than brain and spinal cord tissue that has been taken after the patient has died or the animal sacrificed,`` said Sandy Stewart, Paradigm`s Director of Biochemistry. ``We are making significant progress in developing a rapid and high-throughput test format using Prionics` immunological reagents to increase prion detection sensitivity, reduce incubation time, and allow testing of blood instead of tissues for the pre-symptomatic detection of the diseases.``

``We are very excited to extend our collaboration with Paradigm Genetics because of their outstanding expertise in high-throughput screening technologies and vast knowledge in developing immunoassays,`` said Bruno Oesch, Chairman of Prionics.

Development of animal and human diagnostic products is still in the early stages.

Prionics has pioneered prion diagnostics and markets Prionics®-Check, the European Union-approved test for BSE-surveillance that is broadly used in France, Switzerland, Denmark, Netherlands, Spain, Portugal, Austria, Italy, Finland and Germany. Prionics has developed proprietary antibodies that recognize and differentiate a normal prion protein from a disease-specific prion protein. The European Commission confirmed the current Prionics test to be 100% specific and sensitive in detecting diseased animals.

[TheFrog]

Schauen sie doch einfach mal rein: www.brokerstalk.de.vu

[woolfe]

Jetzt ohne neue Nachrichten kräftig angesprungen.

[woolfe]

Related Quotes

PDGM
11 1/4
+1/8

delayed 20 mins - disclaimer


Monday February 5, 2:58 pm Eastern Time
Companies race to develop better mad cow test
By Maggie Fox, Health and Science Correspondent

WASHINGTON, Feb 5 (Reuters) - As mad cow disease spreads from Britain and threatens the European cattle industry, scaring meat-eaters who fear they may catch the brain-wasting illness from eating beef, several companies are working to develop an easier test for the disease.

The only surefire way now to test for mad cow disease, known officially as bovine spongiform encephalopathy (BSE), is to check an animal`s brain after it has been killed.

The same goes for the human version of the disease, Creutzfeldt-Jakob disease (CJD) and the new human strain, variant CJD (vCJD), caused by eating infected beef.

``Everyone is racing to get a blood test,`` Sandy Stewart, a vice president at Paradigm Genetics Inc. (NasdaqNM:PDGM - news), one company hoping to market a test, said in a recent telephone interview.

``It`s a big issue. It was the same with HIV.``

And although vCJD has been detected in fewer than 90 people -- most in Britain and three in France -- a test could guide doctors who suspect a patient has the incurable illness.

``Unfortunately, at present the only way to diagnose mad cow disease in cattle or the human form of the disease ... is after the symptoms have developed and the disease is entering its late stages,`` Dr. Robert Petersen, chief scientific adviser at Prion Developmental Laboratories, Inc., one of the companies hoping to develop a test, said in a statement.

``By then it`s usually too late to ensure that infected meat or beef products have not entered the human food supply,`` Petersen, a pathologist at Case Western Reserve University in Ohio, added.

``There is still no treatment for prion diseases, including BSE and vCJD, but a reliable and sensitive diagnostic would permit the testing not only of cattle, but also of human blood products and tissues before they are used in medical procedures.``

MAD COW CAUSE NOT EASY TO TEST FOR

But BSE is not caused by something easy to test for, such as bacteria. It is not even caused by a virus, which is somewhat easier to test using immune proteins called antibodies or by looking for its genetic material.

BSE, CJD and related diseases such as scrapie are caused by prions, nerve system proteins that are normally benign but which can take on a misshapen form that can cause holes to form in the brain.

Nonetheless, a few companies are forging ahead to develop tests that might find the prions in the blood or in an easily reached part of the body such as the back of the throat.

Privately owned German pharmaceuticals firm Boehringer Ingelheim said in December it had applied for a global patent for a blood test to detect BSE in living cattle.

The company has not detailed just what the test looks for, but says its animal health subsidiary Vetmedica GmbH had developed the test, which it hopes will be available later this year in Europe.

German biotech company GeneScan Europe AG, said earlier it hoped to test its assay for mad cow disease in January.

IDEXX Laboratories Inc. (NasdaqNM:IDXX - news) of Westbrook, Maine, and Caprion Pharmaceuticals of Canada said they were working to develop a blood test but declined to identify the ``novel agents`` that recognize the prion protein.

``That`s our goal, to develop a blood test, but we`re still in the development area,`` Quentin Tonelli, vice president of research and development at IDEXX, said in a telephone interview. ``We hope to have a faster and more sensitive test.``

Paradigm, based in San Francisco, made a pact with Prionics AG, a private Swiss firm, to use Prionics` ``proprietary antibodies`` that can find rogue prions.

FAST APPROVAL OF NEW TESTS EXPECTED

Roche Holdings AG recently agreed to market the test. ``We`d anticipate (regulators) would accelerate the (approval) process,`` Stewart said. ``We don`t anticipate a tremendous lag in getting a test to the market because there`s a food safety issue here.``

Bayer Corporation and Rockville, Maryland-based BioReliance (NasdaqNM:BREL - news) said they had developed a test for prions that could be used to see whether blood purification methods worked to remove the infectious prions.

At least one company has been formed specifically to find a test for the disease. Dr. Robert Gallo, who helped discover the HIV virus that causes AIDS, has helped set up Prion Developmental Laboratories, Inc. to find a BSE test.

Working with BioLabs, Inc., the researchers hope to come up with a test that can be used on cattle at the slaughterhouse, and then later perhaps human blood.

Gallo`s team has not said what they will use as the basis for their test. But in November, Swiss scientists reported they had discovered a blood protein, called plasminogen, that attaches to the rogue prions.

[thebull 2]

news gibts genug.warum interessiert sich keiner dafür???
last news

Tuesday November 6, 8:49 am Eastern Time

Press Release

SOURCE: Paradigm Genetics, Inc.

Paradigm and Thermo Electron Announce Strategic Alliance to Develop the
Next Generation of Technologies for Metabolomics

Companies Will Integrate Thermo Electron Instruments With Paradigm`s Expertise To Design and
Validate Equipment For Use in Metabolomics

RESEARCH TRIANGLE PARK, N.C., Nov. 6 /PRNewswire/ --

Paradigm Genetics, Inc. (Nasdaq: PDGM - news) today announced the initiation of a strategic alliance with Thermo Electron Corporation (NYSE: TMO - news) to
design and develop the next generation of chromatography/mass spectrometry systems for use in the field of metabolomics. Under the terms of the agreement,
Paradigm will provide technical and implementation consulting services to Thermo Electron`s chromatography/mass spectrometry business, Thermo Finnigan, and
have exclusive pre-commercial access to the new instruments and systems in the field of metabolomics. Thermo Finnigan will utilize Paradigm`s metabolomics
platform technology to design and validate its equipment and technology. Financial details of the deal were not disclosed.

``With Paradigm`s help, we are designing and developing systems that are sure to become the industry standard for conducting research in the growing field of
metabolomics,`` said Ian Jardine, Ph.D., president of Thermo`s Analytical Instruments division. ``Metabolomics technologies are increasingly becoming valuable tools
for the life sciences industry, and we are committed to applying our expertise in chromatography and mass spectrometry to address emerging needs that rely on
accurate, rapid, and meaningful analysis.``

Under the terms of the alliance, Thermo Finnigan`s technologies in chromatography and mass spectrometry systems and Paradigm`s metabolomics technologies will
be integrated to create a platform technology for identifying and validating metabolite biomarkers.

``This collaboration is an unique opportunity to leverage the expertise of our two companies to help create a new generation of systems to address the
post-genomics research needs of the life sciences industry,`` commented John Ryals, Ph.D., CEO and President of Paradigm. ``Sharing our experiences with Thermo
Finnigan and getting early access to their instrumentation will enable us to further accelerate and enhance our own metabolomics programs in human health,
agriculture and nutrition.``

The field of metabolomics, namely the study of all small molecules and their interactions within an organism, has applications in most areas of life science research,
including human health, nutrition and agriculture. Metabolomics research is expected to play a crucial role in the development of better and safer drugs by focusing on
metabolite biomarkers. Chromatography/Mass spectrometry technologies are key to performing accurate, rapid and meaningful metabolomics analysis.

About Thermo Electron

Thermo Electron is a leading supplier of tools for the drug discovery process, from sample preparation through advanced analysis to bioinformatics software.
Through its Thermo Finnigan brand, the company provides mass spectrometers, liquid chromatography systems, gas chromatography systems, and multi-instrument
combinations of these products, as well as a complete range of advanced software enhancements.

About Paradigm Genetics, Inc.

Paradigm Genetics, Inc. (Nasdaq: PDGM - news), headquartered in Research Triangle Park, NC, is a life sciences company developing new technologies to
discover products for the advancement of agriculture, human health and nutrition. Paradigm uses its proprietary functional genomics and metabolic profiling platform
technologies, GeneFunction Factory(TM), and informatics system to create a wide-range of life science products and services. The company leverages its
technology to deliver customized solutions to agricultural companies. In human health, the company is helping accelerate drug discovery and development. And in
nutrition, Paradigm is working to discover, develop and commercialize plant and microbial-based nutraceutical products. For more information, visit
www.paradigmgenetics.com.

This press release contains forward-looking statements, including statements regarding Paradigm`s ability to successfully develop its GeneFunction Factory(TM) and
other technologies; Paradigm`s ability to industrialize the process of gene function discovery for four major sectors of the global economy: human health, nutrition,
crop production, and industrial products; the prospects of Paradigm and its partners to develop products; Paradigm`s ability to meet or exceed the expectations of its
partners; as well as Paradigm`s prospects for growth and innovation. Such statements are based on management`s current expectations and are subject to a number
of risks, factors and uncertainties that may cause actual results, events and performance to differ materially from those referred to in the forward-looking statements.
These risks include, but are not limited to, Paradigm`s early stage of development, history of net losses, technological and product development uncertainties, reliance
on research collaborations, uncertainty of additional funding and ability to protect its patents and proprietary rights. These and other risks are identified in Paradigm`s
report on Form 10-Q for the quarter ended June 30, 2001, filed with the Securities and Exchange Commission.

GeneFunction Factory(TM) and FunctionFinder(TM) are U.S. trademarks of Paradigm Genetics, Inc.

SOURCE: Paradigm Genetics, Inc.



gruss
tb 2

[thebull 2]

Wednesday November 7, 1:30 am Eastern Time

Press Release

SOURCE: Paradigm Genetics, Inc.

Paradigm Genetics and LION bioscience Expand Strategic Alliance; Joint
Biochemical Profiling Database to Include Human Cell Lines

RESEARCH TRIANGLE PARK, N.C., and HEIDELBERG, Germany, Nov. 7


/PRNewswire/ -- Paradigm Genetics, Inc. (Nasdaq: PDGM - news) and
LION bioscience AG (Nasdaq: LEON, Neuer Markt: 504 350, LIO) today announced
that they have expanded their five-year strategic alliance, initiated in
January 2000, to co-develop and co-market MetaTrace(TM), a metabolic profiling
database. Under the terms of the expanded agreement, biochemical data will be
added to the MetaTrace(TM) database enabling pharmaceutical research and
discovery based on metabolic information. Financial terms have not been
disclosed.

MetaTrace(TM) will consist of biochemical profiling data predominantly from human cells, fluids and tissues. This data will be
accessible through an IT-interface, which will allow the rapid identification and understanding of disease related genes, their related
biochemical profiles and with that, the development of diseases. Based on these data, the companies believe a more rapid and
profound selection of compounds will be qualified and will have a greater chance of moving successfully through the clinical
development process to become approved drugs.

``We expect MetaTrace(TM) to become the reference database for all biochemical profiles in humans. By analyzing the
biochemical profiles in healthy and diseased tissues, as well as in human cell lines and fluids with our metabolomics technologies,
and integrating it with LION`s leading integrated life science informatics software, researchers can identify disease related pathways
and potential drug candidates early in the process,`` said John A. Ryals, Ph.D. President and CEO of Paradigm Genetics. ``We
have recognized the tremendous opportunity that this level of information can bring to the drug discovery and development process
and expect MetaTrace(TM) to provide the pharmaceutical industry with new approaches for screening of diseased cell lines and in
selecting drug compounds.``

MetaTrace(TM) is believed to be the first database of its kind on the market. It combines LION`s expertise in data analysis,
visualization and research in the field of human health with the metabolomics expertise of Paradigm. The MetaTrace(TM) database,
along with the accompanying visualization software, is expected to supply information for target identification and validation to the
human health industry. Paradigm will determine biochemical profiles in a wide range of tissue samples of healthy and diseased
tissues. By applying arraySCOUT(TM), LION`s software for expression analysis, interesting genes can be identified, related
protein and pathways will then be shown via pathSCOUT(TM), LION`s software for the visualization of biological pathways.
Through the integration of these genes with the metabolite profiling data generated by Paradigm the connection between
up-regulated genes and the presence of certain metabolites, the cause and development of diseases may be understood more rapidly.

``The application of our integrated software modules pathSCOUT(TM) and arraySCOUT(TM), as part of our life sciences informatics platform, for the
understanding and visualization of biochemical profiles and expressed genes, enables the easy identification and analysis of possible drug targets and leads. The
extended collaboration with Paradigm on MetaTrace(TM) powerfully demonstrates generation, analysis and sharing of data and information using our integrated
software modules and allows the rapid generation of knowledge,`` said Dr. Friedrich von Bohlen, Chief Executive Officer of LION. ``Through the unique
combination of our leading data analysis, visualization and information management expertise and MetaTrace(TM), researchers in human health and agriculture will
be supported with comprehensive tools for a broader understanding of health and the development of diseases.``

About LION bioscience

LION bioscience (http://www.lionbioscience.com) provides proven information and knowledge management solutions to significantly improve life science R&D
performance and productivity. These solutions integrate all R&D disciplines, spanning from genomics to early and late discovery through clinical trials. LION applies
these solutions for its internal drug discovery program in the field of nuclear receptors with the goal to out-license specific databases, polymorphism marker panels,
and validated targets and leads.

Founded in 1997, LION has more than 485 employees, with headquarters in Heidelberg, Germany, and subsidiaries in Cambridge, UK, Cambridge, MA, USA and
San Diego, CA, USA. To date, LION has established partnerships with leading life science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera,
DuPont, GlaxoSmithKline, Janssen, Merck Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche, Sumitomo Pharmaceuticals and Tripos.

About Paradigm Genetics, Inc.

Paradigm Genetics, Inc. (Nasdaq: PDGM - news), headquartered in Research Triangle Park, NC, is a life sciences company developing new technologies to
discover products for the advancement of agriculture, human health and nutrition. Paradigm uses its proprietary functional genomics and biochemical profiling
platform technologies, GeneFunction Factory(TM), and informatics system to create a wide-range of life science products and services. The company leverages its
technology to deliver customized solutions to agricultural companies. In human health, the company is helping accelerate drug discovery and development. And in
nutrition, Paradigm is working to discover, develop and commercialize plant and microbial-based nutraceutical products. For more information, visit
www.paradigmgenetics.com.

This press release contains forward-looking statements, including statements regarding Paradigm`s ability to successfully develop its GeneFunction Factory(TM) and
other technologies; Paradigm`s ability to industrialize the process of gene function discovery for four major sectors of the global economy: human health, nutrition,
crop production, and industrial products; the prospects of Paradigm and its partners to develop products; Paradigm`s ability to meet or exceed the expectations of its
partners; as well as Paradigm`s prospects for growth and innovation. Such statements are based on management`s current expectations and are subject to a number
of risks, factors and uncertainties that may cause actual results, events and performance to differ materially from those referred to in the forward-looking statements.
These risks include, but are not limited to, Paradigm`s early stage of development, history of net losses, technological and product development uncertainties, reliance
on research collaborations, uncertainty of additional funding and ability to protect its patents and proprietary rights. These and other risks are identified in Paradigm`s
report on Form 10-Q for the quarter ended June 30, 2001, filed with the Securities and Exchange Commission.

GeneFunction Factory(TM) and FunctionFinder(TM) are U.S. trademarks of Paradigm Genetics, Inc.

SOURCE: Paradigm Genetics, Inc.

gruss
tb 2

[SunshineGerda]

Jetzt wieder hochinteressant:

PARADIGM GENETICS WKN 936980!!!

In den USA aus Abwärtstrend ausgebrochen, letzter Kurs 70 cents, nachbörslich 81 cents!!!

Die Aktie hat gestern hervorragende NEWS verkündet:

Paradigm Signs $8.4 Million Addition to $23.8 Million Contract With NIEHS $2 Million of Additional
Funds Earmarked for Toxicogenomics Studies For the NTP

RESEARCH TRIANGLE PARK, N.C., Apr 24, 2003 /PRNewswire-FirstCall via COMTEX/ --
Paradigm Genetics, Inc. (Nasdaq: PDGM) today announced that the National
Institute of Environmental Health Sciences (NIEHS) has exercised an option in
its existing five-year $23.8 million contract (Contract NO1-ES-25497) with
Paradigm, providing for an additional $8.4 million for toxicogenomics studies.
Two million dollars of this modification is currently allotted and earmarked for
Paradigm to perform research for the National Toxicology Program (NTP). Data
generated from this toxicogenomics research will be included in the NTP`s
program to better understand the effects of short and long-term exposures to
chemicals. The data will become part of the Chemical Effects in Biological
Systems (CEBS) database, a publicly accessible relational database that will
contain information on the biological effects of chemicals and other agents and
their mechanism of action.

"Part of the NTP`s mission is to strengthen the science base in toxicology and
provide information about potentially toxic chemicals to health regulatory and
research agencies, the scientific and medical communities, and the public," said
Kenneth Olden, Ph.D., Director, NIEHS and NTP. "Working with Paradigm Genetics,
we seek the best possible biological information to fulfill our mission."

"We are proud and honored that the NTP recognizes our expertise in DNA
microarray analysis and chose to work with us for its toxicogenomics research,"
said Heiri Gugger, Ph.D., President and CEO of Paradigm Genetics. "This
additional $8.4 million modification is a great confirmation of our momentum in
the field of toxicogenomics and our growing presence in human health."

The NTP is an interagency program consisting of relevant toxicology activities
among the National Institutes of Health`s National Institute of Environmental
Health Sciences, the Centers for Disease Control and Prevention`s National
Institute for Occupational Safety and Health, and the Food and Drug
Administration`s National Center for Toxicological Research.

About Paradigm Genetics

Paradigm is a biotechnology company aiming to increase R&D productivity by
focusing its integrated suite of technologies on the product development cycle,
from target discovery to subsequent enhancement of the safety and efficacy
profiles of development candidates in agriculture and human health. Paradigm
chooses a systems biology approach to understand gene function in the context of
biological pathways, to develop assays and biomarkers for molecular diagnostic
solutions tailored to the needs of our partners. Paradigm`s proprietary Gene to
Cell to System(TM) approach has three major components: gene expression
profiling, biochemical profiling (also known as metabolomics) and data
integration and coherence. For more information, visit www.paradigmgenetics.com.

This press release contains forward-looking statements, including statements
regarding the use and impact of data generated from the toxicogenomics research.
Such forward-looking statements are based on management`s current expectations
and are subject to a number of risks, factors and uncertainties that may cause
actual results, events and performance to differ materially from those referred
to in the forward-looking statements. These risks, factors and uncertainties
include, but are not limited to, Paradigm`s early stage of development, history
of net losses, technological and product development uncertainties, reliance on
research collaborations, uncertainty of additional funding and ability to
protect its patents and proprietary rights. Certain of these and other risks are
identified in Paradigm`s Form 10-K for the year ended December 31, 2002, filed
with the Securities and Exchange Commission. The Company does not intend to
update any of the forward-looking statements after the date of this release to
conform these statements to actual results or to changes in our expectations,
except as may be required by law.

SOURCE Paradigm Genetics, Inc.



CONTACT: Melissa Matson, Director, Corporate Communications of

Paradigm Genetics, Inc., [phone], or media, Prateek Patnaik,

or investors, Amy Garay, of Noonan Russo Presence Euro RSCG, [phone],

for Paradigm Genetics, Inc.



URL: http://www.paradigmgenetics.com

http://www.prnewswire.com


Copyright (C) 2003 PR Newswire. All rights reserved.


Das ist aber längst nicht alles:

- Paradigm WKN 936980 hält Cash ca. in Höhe von über 1,2$ pro Aktie

- Paradigm WKN 936980 forscht auch im Bereich SARS und das birgt eine Menge Fantasie!!!

- Am 1.5. sollen neben deutlich besser als erwarteten Zahlen auch NEWS zu Forschungsergebnissen kommen!!!

Fazit: Die 1€.-Marke dürfte im Vorfeld des 1.5. erreicht werden, der Wert ist deutlich im Aufwärtstrend!!!

Siehe auch Chart:



Bis 80 cents kaufen und mitverdienen - es geht gerade richtg los!

PARADIGM GENETICS WKN 936980

Sunshine!Gerda

Hört sich alles sehr gut an:

Apr 23 2003
TRADE NEWS: Agilent Technologies Offers
Industry`s First 60-mer Oligonucleotide Rat
Microarray for Genome Screening, Toxicogenomic
Research Microarrays Incorporate Unique, Proven
Toxic Response Genes from the NIEHS to Assist
Scientists in the Discove
Apr 23 2003
You Are Cordially Invited to the Paradigm Genetics
First Quarter 2003 Financial Results Conference Call
Webcast
Apr 15 2003
Paradigm Strengthens Human Health Unit Through
Key Appointments In Medical Informatics and
Computational Biology Industry Expert Michael
Liebman Appointed to Scientific Advisory Board And
Brian Bullard Hired as Senior Director of
Computational System

[SunshineGerda]

PARADIGM WKN 936980 forscht auf dem Gebiet, welches für die SARS-Bekämpfung zuständig ist!
Spätestens am 1.5. sind NEWS mit den Zahlen zu erwarten!

Aktuell 90 cents - im Moment aber nochmals zu 76 cents im Angebot!

Heute deutlich über 1$ in USA!

Sunshine!Gerda